{"id":17736,"date":"2026-02-03T01:47:05","date_gmt":"2026-02-03T01:47:05","guid":{"rendered":"https:\/\/gray-nightingale-130192.hostingersite.com\/?p=17736"},"modified":"2026-02-03T01:47:05","modified_gmt":"2026-02-03T01:47:05","slug":"fda-wants-pause-on-landmark-abortion-pill-suit-pro-lifers-say-it-will-cost-lives","status":"publish","type":"post","link":"https:\/\/biblelon.com\/?p=17736","title":{"rendered":"FDA Wants Pause On Landmark Abortion Pill Suit. Pro-Lifers Say It Will Cost Lives"},"content":{"rendered":"

\n Reading Time:<\/span> 4<\/span> minutes<\/span><\/span><\/p>\n

(THE FEDERALIST) \u2013 The U.S. Food and Drug Administration wants a federal court to halt a\u00a0lawsuit\u00a0from Louisiana and an abortion pill poisoning survivor demanding the agency end the Biden administration\u2019s \u201cillegal\u201d mail-order abortion pill permissions. The plaintiffs and pro-lifers who back the case, however, say a pause and denial of preliminary injunction will only put women and babies at more risk.\n<\/p>\n

Join others crying out to the\u00a0<\/span>Lord day<\/span>\u00a0and night<\/span>.\u00a0<\/span><\/h4>\n

\u00a0<\/p>\n

In its\u00a0memorandum\u00a0filed on Tuesday, the FDA claimed legal challenges to the radical expansions that make it easier for people to obtain mail-order mifepristone and initiate at-home abortions without medical oversight are \u201cdisruptive\u201d and possibly \u201cunnecessary\u201d in light of the agency\u2019s ongoing mifepristone review.\n<\/p>\n

\u201cThe rationale for deferring judicial review is simple: the \u2018harm of moving forward\u2019 with judicial review of the 2023 REMS Modification outweighs the \u2018harm of holding back,\u2019\u201d the memo states.\n<\/p>\n

No\u00a0review is required\u00a0for the FDA to reinstate some of the common-sense abortion pill safeguards, such as an in-person doctor visit, that were stripped from the FDA\u2019s Risk Evaluation and Mitigation Strategy\u00a0(REMS) under President Joe Biden\u2019s watch. In fact, doing so would match the second Trump administration\u2019s mifepristone parameters with those present during the first Trump administration.\n<\/p>\n

The FDA, however, signaled it does not plan to act on those REMs until its review is complete. The filing goes so far as to claim that plaintiffs such as Rosalie Markezich, who\u00a0lost her baby\u00a0after being allegedly coerced into taking abortion drugs that her boyfriend mail-ordered against her consent, \u201cthreaten to short circuit the agency\u2019s orderly review and study of the safety risks of mifepristone.\u201d\n<\/p>\n

Additionally, the FDA suggested that awarding the growing number of lawsuits the preliminary relief they desire could \u201csow administrative and judicial chaos\u201d such as the\u00a0conflicting injunctions\u00a0out of Texas and Washington in respective challenges to the FDA\u2019s 2000 mifepristone approval and 2023 REMS.\n<\/p>\n

The 20-page document ends with the defendants declaring that Markezich, despite\u00a0<\/strong>suffering an abortion pill poisoning, lacks standing. According to the FDA\u2019s counsel, Markezich\u2019s assertions that she could face another forced chemical abortion under the FDA\u2019s current policies is \u201cinsufficient to satisfy the injury-in-fact requirement.\u201d\n<\/p>\n

\u201cFDA\u2019s review will necessarily result in a new agency decision that could supersede the 2023 REMS Modification, obviating any need to consider the merits of Plaintiffs\u2019 arguments challenging the validity of the 2023 REMS Modification,\u201d the memorandum states. \u201cAny party adversely affected by the new agency decision on mifepristone may seek judicial review
at that time. And in the event of a further REMS modification, adherence to FDA\u2019s normal process will create far less disruption than the abrupt, judicially imposed change sought by Plaintiffs.\u201d\n<\/p>\n

Pro-lifers vehemently disagree. While the FDA mifepristone review is considered a small victory for the organizations hoping to save women and babies from the suffering linked to mifepristone, it is not enough to stop the most popular abortion drug in the U.S. Stories of\u00a0women, even those in states where chemical abortion is banned,\u00a0suffering\u00a0injuries and even death\u00a0after\u00a0taking\u00a0or\u00a0being\u00a0force\u00a0fed\u00a0abortion pills\u00a0without medical supervision continue to surface alongside studies showing mifepristone is\u00a0more dangerous than previously thought.\n<\/p>\n

\u201cThere is no reason that the FDA couldn\u2019t immediately reinstate [mifepristone\u2019s] in-person dispensing requirement while at the same time doing a thorough safety review to see if more safeguards need to be put back into place,\u201d American Association of Pro-Life OBGYNs CEO Dr. Christina Francis declared.\n<\/p>\n

SBA Pro-Life America President Marjorie Dannenfelser warned that \u201cWomen and children are dying and do not have \u2018a year or more\u2019 to wait on the FDA.\u201d\n<\/p>\n

\u201cThey deserve safeguards NOW,\u201d she\u00a0said.\n<\/p>\n

Kristen Waggoner, President, CEO, and Chief Legal Counsel of Alliance Defending Freedom, encouraged the Trump administration\u00a0on X\u00a0to \u201cstand with Louisiana\u2014not with abortion extremists like Gavin Newsom and Letitia James.\u201d\n<\/p>\n

Louisiana Attorney General Liz Murrill\u00a0framed the FDA\u2019s memo\u00a0as \u201can affront to our sovereignty and the dignity of women and the unborn.\u201d\n<\/p>\n

\u201cFDA should stand with us for life, not with\u00a0@CAgovernor\u00a0and\u00a0@GovKathyHochul,\u201d Murrill wrote.\n<\/p>\n

Mere weeks ago, Murrill warned in a Senate hearing that until the FDA reimposes the mifepristone safeguards stripped away by Biden, \u201cLouisiana\u2019s efforts to protect mothers and their unborn children and to hold out-of-state abortion pill traffickers accountable for the harm they inflict will be all but futile.\u201d\n<\/p>\n

A\u00a0recent McLaughlin and Associates survey\u00a0found that 71 percent of likely voters approve of the FDA requiring a doctor visit to obtain an abortion drug prescription. Three-in-five respondents even went so far as to agree that \u201cchemical abortions are far more dangerous than advertised, and women deserve a doctor\u2019s care to prevent serious health complications like hemorrhaging, bleeding, or infections.\u201d\n<\/p>\n

Approximately seven in 10 of those surveyed, after agreeing that \u201cchemical abortion drugs are used by sexual abusers to cover up rape, exploitation and sex-trafficking,\u201d said doctors should also be required to \u201cscreen for and report signs of coercion or abuse\u201d before prescribing mifepristone.\n<\/p>\n

The FDA\u00a0previously failed to answer\u00a0The Federalist\u2019s questions about how long the review is estimated to take. The Tuesday memorandum\u00a0emphasized\u00a0that the agency is working on a Mifepristone study that would usually \u201ctake approximately a year or more to conduct.\u201d Makary\u2019s FDA, however, is aiming to complete it in a \u201csooner than that timeframe.\u201d\n<\/p>\n

Share your prayers to protect the unborn below.<\/h4>\n

This article was originally published in The Federalist.<\/em>
\n \n <\/p>\n","protected":false},"excerpt":{"rendered":"

Reading Time: 4 minutes (THE FEDERALIST) \u2013 The U.S. Food and Drug Administration wants a federal court to halt a\u00a0lawsuit\u00a0from Louisiana and an abortion pill poisoning survivor demanding the agency end the Biden administration\u2019s \u201cillegal\u201d mail-order abortion pill permissions. The plaintiffs and pro-lifers who back the case, however, say a pause and denial of preliminary<\/p>\n","protected":false},"author":1,"featured_media":17737,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[205,2492,5677,2110,3020,4658,1905,4849,743],"class_list":["post-17736","post","type-post","status-publish","format-standard","has-post-thumbnail","category-prayer","tag-abortion","tag-cost","tag-fda","tag-landmark","tag-lives","tag-pause","tag-pill","tag-prolifers","tag-suit"],"_links":{"self":[{"href":"https:\/\/biblelon.com\/index.php?rest_route=\/wp\/v2\/posts\/17736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biblelon.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biblelon.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biblelon.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/biblelon.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17736"}],"version-history":[{"count":0,"href":"https:\/\/biblelon.com\/index.php?rest_route=\/wp\/v2\/posts\/17736\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/biblelon.com\/index.php?rest_route=\/wp\/v2\/media\/17737"}],"wp:attachment":[{"href":"https:\/\/biblelon.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biblelon.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biblelon.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}